Last updated: May 29, 2026
XYOSTED (testosterone) autoinjector is supplied through a branded product ecosystem built around contract manufacturing for drug product and a multi-tier supply chain for autoinjector hardware components. Publicly available sources that name specific autoinjector and subcomponent suppliers are not sufficient to produce a complete, accurate “who supplies what” roster for XYOSTED without risking fabrication.
XYOSTED autoinjector supply chain: which companies manufacture the drug product and injector system?
What is known from public disclosures
- XYOSTED is an FDA-approved testosterone injection delivered via a spring-driven autoinjector.
- The supply chain necessarily includes:
- API sourcing for testosterone (thyroid of the manufacturing chain: upstream chemical supply)
- sterile injectable drug product manufacturing (formulation, aseptic fill, terminal sterilization or aseptic processing depending on process)
- autoinjector assembly and integration (pen body, needle, shielding, actuation mechanism, sensors, springs, safety interlocks)
- packaging (sterile inner, outer cartons, labeling)
What cannot be provided reliably
- A named list of specific contract manufacturing organizations (CMOs) and autoinjector hardware OEMs for XYOSTED is not consistently disclosed in public documents in a way that supports an accurate supplier mapping.
Which suppliers provide the autoinjector components for XYOSTED (needle, spring, housing, safety mechanism)?
Needle and cartridge interface
- Autoinjector systems for injections typically include a hypodermic needle module and a cartridge or drug container interface.
- Safety mechanisms typically require a needle shield and lockout after actuation.
- However, publicly indexed sources do not provide a supplier-by-supplier breakdown for XYOSTED’s needle module, spring/actuation train, housing molding, or shielding components.
Molded plastics and metal parts
- Pen bodies and internal frames usually come from injection molding and precision metal fabrication suppliers.
- Without authoritative, source-backed disclosures, a named vendor list would be guesswork.
How does XYOSTED’s contract manufacturing structure typically split across API, sterile fill-finish, and final device assembly?
Common industry split
- API supplier (testosterone)
- Drug substance to drug product intermediate handling
- Sterile fill-finish (aseptic fill into the device’s drug container or cartridge)
- Device assembly and integration (combining drug-filled unit with needle, actuation mechanism, and safety cover)
- Final packaging and serialization for US distribution
XYOSTED-specific mapping
- Public records do not provide a complete public vendor roster that ties these steps to specific named companies for XYOSTED.
What Orange Book information exists for XYOSTED that indicates manufacturing or supplier relationships?
- Orange Book listings for a branded injectable generally do not enumerate specific manufacturing sites or component suppliers in a way that enables identification of the autoinjector OEM or subcomponent sources.
Are there generic or biosimilar “autoinjector” suppliers competing with XYOSTED hardware, and what does that imply for XYOSTED supplier leverage?
- For testosterone injectables, competitive entry has historically focused on dosage form, dosing consistency, and regulatory pathway.
- Supplier leverage analysis depends on identifying which autoinjector platform vendors and CMOs are qualified for the hardware plus device integration.
- Named supplier competition for XYOSTED’s exact autoinjector design is not determinable from public sources at a level sufficient for a precise supplier landscape.
What patent or regulatory constraints can limit alternative suppliers for XYOSTED’s device or manufacturing?
- Autoinjectors and combination products can be constrained by:
- device design patents
- manufacturing method patents
- regulatory controls for device performance and human factors
- cGMP master file access and validation dependencies
- A specific constraint mapping to named supplier capabilities is not supportable without a disclosed supplier roster and a complete set of relevant patents and filings tied to supply vendors.
Commercial and operational “supplier bottleneck” risks for XYOSTED if a key hardware supplier fails
Typical single-point-of-failure areas for autoinjectors:
- needle supply (steel/hypodermic needle procurement and coating, sterility assurance)
- safety shield and locking mechanism production
- spring/actuation mechanism precision fabrication
- sterility assurance for the drug-filled device integration step
- packaging and labeling line availability
XYOSTED-specific supplier bottlenecks cannot be quantified without authoritative supplier identification.
Key Takeaways
- A supplier landscape for XYOSTED’s autoinjector hardware and sterile drug product cannot be produced accurately from publicly available, source-backed information.
- Any named “supplier list” that claims specific companies for XYOSTED’s needle module, autoinjector OEM platform, or drug product CMOs would be speculative.
FAQs
- Who manufactures XYOSTED in the US and where are the cGMP sites?
- What autoinjector technology platform does XYOSTED use, and which device OEMs typically build that platform?
- Which suppliers provide the needle and safety shield components for spring-driven testosterone autoinjectors?
- How does FDA combination product oversight affect selecting alternate autoinjector suppliers for XYOSTED?
- What supply risks (sterility, needle delivery, device integration) most commonly disrupt autoinjector drug availability?
References
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Database). https://www.accessdata.fda.gov/scripts/cder/daf/
- FDA. Drug Approval Packages (Drugs@FDA). (Database). https://www.accessdata.fda.gov/scripts/cder/daf/
- FDA. Combination Products Policy. (Guidance and policy pages). https://www.fda.gov/combination-products
